Onderneming Nabriva Therapeutics PLC - ADR Nasdaq
Aandelen
US62957M1045
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
USD in miljoen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
Novel Anti-infective Agents
100,0
%
| 29 | 100,0 % | 37 | 100,0 % | +27,82% |
Verkoop per regio
USD in miljoen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
Austria, Ireland, and United States
100,0
%
| 29 | 100,0 % | 37 | 100,0 % | +27,82% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
H. Hogan
CEO | Chief Executive Officer | 61 | 07-07-23 |
Dave Maggio
DFI | Director of Finance/CFO | 64 | 30-06-23 |
Steven Gelone
BRD | Director/Board Member | 56 | 23-06-17 |
Director/Board Member | 69 | 24-07-18 | |
Kim Anderson
IRC | Investor Relations Contact | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Daniel Burgess
CHM | Chairman | 62 | 23-06-17 |
Director/Board Member | 69 | 24-07-18 | |
Stephen Webster
BRD | Director/Board Member | 63 | 01-08-16 |
Charles Rowland
BRD | Director/Board Member | 65 | 01-01-15 |
Steven Gelone
BRD | Director/Board Member | 56 | 23-06-17 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 3 230 837 | 3 200 138 ( 99,05 %) | 0 | 99,05 % |
Bedrijfsgegevens
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+4,14% | 106 mld. | |
+6,84% | 23,47 mld. | |
-14,47% | 21,9 mld. | |
-6,50% | 18,77 mld. | |
-38,55% | 17,85 mld. | |
-8,54% | 16,78 mld. | |
+7,34% | 14,41 mld. | |
+38,96% | 12,86 mld. | |
+324,56% | 8,78 mld. |